Navigation Links
Birth control has long-term effect on hormone exposure
Date:10/20/2008

WINSTON-SALEM, N.C. Researchers at Wake Forest University School of Medicine may be one step closer to understanding why past oral contraceptive use dramatically lowers the risk of ovarian and uterine cancers later in life.

While studying the effect of post-menopausal dietary soy consumption on estrogen metabolism in cynomolgus monkeys, Latanya M. Scott, Ph.D., discovered that monkeys who had been given birth control earlier in life had a reduced amount of estrogen excreted in their urine. The research was done in collaboration with Xia Xu, Ph.D., and Timothy Veenstra, Ph.D. at Science Applications International Corporation-Frederick, Inc., in Frederick, Md., who have developed novel methods for analysis of urinary estrogens.

The discovery was particularly noteworthy because it was found three years after oral contraceptive treatment was stopped, roughly the equivalent of a decade of life in a human.

While researchers have known for many years that past oral contraceptive use significantly lowers the risk of ovarian and uterine cancers later in life, this new observation in monkeys may shed light on the mechanism behind the cancer-protective effect of the treatment. Past oral contraceptive use appears to result in a long-term change in the way the monkeys' bodies process hormones. While researchers don't yet understand the precise mechanism by which hormone levels are being affected, they do know that both the level of estrogen in the blood and the amount of estrogen being excreted in urine are lowered with past oral contraceptive use, which may mean that the oral contraceptive use is somehow leading to a diminished synthesis of estrogen.

The study appears in this month's issue of Cancer Epidemiology, Biomarkers and Prevention.

"Hormone exposure has long been known to be important in cancer risk," said J. Mark Cline, D.V.M., Ph.D., and senior researcher on the project. "These effects are robust, and we b
'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Risk of common vaginal infection linked to preterm birth appears higher for blacks
2. Birth records hold pancreatic cancer clue
3. Researchers find evidence linking stress caused by the Sept. 11 disaster with low birth weights
4. Birth of an iceberg
5. The birth and death of dopamine neurons: A new model for neurodegeneration
6. Certain diseases, birth defects may be linked to failure of protein recycling system
7. New folic acid seal helps women choose enriched grain foods to help prevent birth defects
8. Immunosuppressant further linked to birth defects
9. Northern right whales head south to give birth, leave genetic fingerprints with NOAA researchers
10. Deadly genetic disease prevented before birth in zebrafish
11. Birth of an enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... discovered the presence of functional ion channels in human ... electrical wires and permit ESCs, versatile cells that possess ... the body, to conduct and pass along electric currents. ... channels in implanted cells, derived from stem cells, they ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
... medieval Europe ?to fade from the scene? By the ... The reason seems to be, say researchers at the ... a far more deadly disease, overtook leprosy, killing millions ... examination of DNA from human remains from the ancient ...
Cached Biology News:Stem cells' electric abilities might help their safe clinical use 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3Once-dreaded leprosy 'replaced' by tuberculosis, say researchers 2
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Anca Copaescu, then a second-year MBA in the University of ... Burrill Technology Business Plan Competition, she knew she wanted to ... though the money definitely got her attention. It was the ... of her deepest dreams. "Even as a child growing up ...
... , ,Its a strategy, process and technology ... across the entire spectrum of local, state, national, and ... life sciences and information technology. We can help our ... tourism, manufacturing, and agriculture to operate in real- time. ...
... most common question Im asked is, Why wont angels invest in ... 90+% of the entrepreneurs asking this question. The irony is that ... though it isnt the answer they are expecting. The less ... is serious and problematic. , , Angels vs. angel networks ...
Cached Biology Technology:Romanian Student Leverages Burrill Competition to Accomplish Her Dream 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 3Real-Time Economy: Part 2 2What Angel Networks Want 2What Angel Networks Want 3What Angel Networks Want 4What Angel Networks Want 5
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Asb-2 (Ankyrin repeat and SOCS box-containing protein) ... peptides containing amino acids 75-93 and 348-368 ... (Imgenex Catalog No. 40149) can be used ... react with mouse and rat Asb-2, based ...
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Biology Products: